Aliskiren
- Generic Name
- Aliskiren
- Brand Names
- Rasilez, Tekturna, Tekturna Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C30H53N3O6
- CAS Number
- 173334-57-1
- Unique Ingredient Identifier
- 502FWN4Q32
- Background
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.
- Indication
Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2010-01-20
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT01040494
- Locations
- 🇨🇳
Taipei Veteral General Hospital, Taipei, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics
- Conditions
- Interventions
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- William Beaumont Hospitals
- Registration Number
- NCT00994253
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT00982033
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Vitamin D Deficiency in Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- UConn Health
- Target Recruit Count
- 40
- Registration Number
- NCT00974922
- Locations
- 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States
Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients
- Conditions
- Interventions
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2013-10-28
- Lead Sponsor
- Cook County Health
- Target Recruit Count
- 2
- Registration Number
- NCT00961207
- Locations
- 🇺🇸
John H Stroger Hospital of Cook County, Chicago, Illinois, United States
The Effect of Renin Inhibition on Nerve Function in Diabetes
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- Christiana Care Health Services
- Target Recruit Count
- 60
- Registration Number
- NCT00935064
- Locations
- 🇺🇸
Christiana Care Health Services, Newark, Delaware, United States
Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT00933920
- Locations
- 🇮🇳
Novartis Investigative Site, New Delhi, India
🇮🇳Novartis Investigator Site, Mangalore, India
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1143
- Registration Number
- NCT00927394
- Locations
- 🇺🇸
Investigative Site, Philadelphia, Pennsylvania, United States
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2012-07-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 123
- Registration Number
- NCT00923156
- Locations
- 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
🇷🇺Novartis Investigator Site, Moscow, Russian Federation
Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 25
- Registration Number
- NCT00922311
- Locations
- 🇨🇳
Department of Medicine, The University of Hong Kong, Hong Kong, China
🇨🇳Queen Mary Hospital, Hong Kong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.